1naresh

Array
(
    [urn:ac.highwire.org:guest:identity] => Array
        (
            [runtime-id] => urn:ac.highwire.org:guest:identity
            [type] => guest
            [service-id] => ajnr-ac.highwire.org
            [access-type] => Controlled
            [privilege] => Array
                (
                    [urn:ac.highwire.org:guest:privilege] => Array
                        (
                            [runtime-id] => urn:ac.highwire.org:guest:privilege
                            [type] => privilege-set
                            [privilege-set] => GUEST
                        )

                )

            [credentials] => Array
                (
                    [method] => guest
                )

        )

)
1nareshArray
(
    [urn:ac.highwire.org:guest:identity] => Array
        (
            [runtime-id] => urn:ac.highwire.org:guest:identity
            [type] => guest
            [service-id] => ajnr-ac.highwire.org
            [access-type] => Controlled
            [privilege] => Array
                (
                    [urn:ac.highwire.org:guest:privilege] => Array
                        (
                            [runtime-id] => urn:ac.highwire.org:guest:privilege
                            [type] => privilege-set
                            [privilege-set] => GUEST
                        )

                )

            [credentials] => Array
                (
                    [method] => guest
                )

        )

)

Table 3: Multivariable analysis of favorable clinical outcome at 3 months
OR (95% CI)^{^a} P Value^{^b} adjOR (95% CI)^{^a} P Value^{^b}
IES 2.99 (0.86–12.3) .08 11.9 (1.6–89.1) .02
Initial NIHSS <15 0.78 (0.67–0.90) .001 12.5 (1.8–87.0) .01
MRI ASPECTS >7 3.2 (0.90–11.3) .007 4.9 (0.8–31.0) .09
Diabetes 0.12 (0.02–0.65) .01 0.13 (0.01–1.7) 10
Time to treatment 1.00 (0.99–1.02) .63 — —
Dyslipidemia 0.45 (0.14–1.49) .19 — —
Sex (male) 0.88 (0.28–2.80) .83 — —
Age 0.98 (0.93–1.03) .45 — —
Current smoker 0.75 (0.23–2.43) .64 — —
Hypertension 0.49 (0.15–1.62) .25 — —
Note:—OR indicates odds ratio; adjOR, adjusted odds ratio.
↵a OR and adjOR values comparing the 3-month clinical outcome between IVT and IES, after adjustment for confounding factors using an exact logistic regression.
↵b P for comparison between IVT and IES (χ² test or Fisher exact test).